Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

IAS 2015: PrEP Adherence, Sexual Behavior, and HIV and STI Incidence [VIDEO]

An open-label Truvada pre-exposure prophylaxis (PrEP) demonstration project, which included more than 500 mostly gay and bisexual men in San Francisco, Miami, and Washington, DC, showed that adherence was generally good overall -- especially among people at highest risk for HIV infection -- but there were some important disparities, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.

alt

Read more:

No New HIV Infections Seen Over 2.5 Years in Kaiser San Francisco PrEP Program

The number of people accessing Truvada pre-exposure prophylaxis (PrEP) through the large Kaiser Permanente San Francisco healthcare system has increased dramatically since 2012, and no new HIV infections have been reported so far, according to study results published in the September 1 advance edition of Clinical Infectious Diseases. Rates of sexually transmitted infections (STIs) were high -- reaching 50% after a year on PrEP -- and some gay men reported a drop-off in condom use, but PrEP offers an opportunity for timely STI diagnosis and treatment, the researchers said.

alt

Read more:

IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk

The first data from a Brazilian open-label demonstration project of HIV pre-exposure prophylaxis (PrEP) show, in common with several other studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver, that the higher a person’s risk of HIV infection, the more likely they are to seek and use PrEP.

alt

Read more:

IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]

Results from the HPTN 067 or ADAPT trial -- a study of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis for gay men in New York City and Bangkok, and heterosexual women in Cape Town -- add to the growing body of evidence about how best to use PrEP and how its protective effect may vary across population groups and with different dosing schedules, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana

A study of open-label Truvada HIV pre-exposure prophylaxis (PrEP) among heterosexual people in Botswana found very high adherence rates. Around 90% of participants had useful levels of the drug in their blood, there was a high concordance between self-reported adherence and drug levels, and there were no HIV infections, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more: